EX-32.1 4 trda-20220930x10qex321.htm EX-32.1
Exhibit 32.1
CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Entrada Therapeutics, Inc. (the “Company”) for the quarterly period ended September 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of their knowledge:
(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: November 7, 2022

| By: | /s/ Dipal Doshi
|  | Dipal Doshi
|  | President and Chief Executive Officer
|  | (Principal Executive Officer)

Date: November 7, 2022

| By: | /s/ Kory Wentworth
|  | Kory Wentworth
|  | Chief Financial Officer
|  | (Principal Financial and Accounting Officer)